Ovid Therapeutics Inc (OVID)

Ovid Therapeutics (OVID) Stock Price & Analysis


OVID Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.41 - $3.40
Previous Close$2.62
Average Volume (3M)68.52K
Market Cap
Enterprise Value$72.22M
Total Cash (Recent Filing)$129.00M
Total Debt (Recent Filing)$16.54M
Price to Earnings (P/E)-3.4
May 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding70,491,510
10 Day Avg. Volume58,806
30 Day Avg. Volume68,521
Standard Deviation0.26
Financial Highlights & Ratios
Price to Book (P/B)1.40
Price to Sales (P/S)122.90
Price to Cash Flow (P/CF)1.30
P/FCF Ratio-3.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue48.06
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.33
Price Target Upside81.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $1.41 and its highest was $3.40 in the past 12 months.
    What is Ovid Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Ovid Therapeutics Inc’s upcoming earnings report date?
    Ovid Therapeutics Inc’s upcoming earnings report date is May 09, 2023 which is in 43 days.
      How were Ovid Therapeutics Inc’s earnings last quarter?
      Ovid Therapeutics Inc released its earnings results on Mar 13, 2023. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.172 by $0.012.
        Is Ovid Therapeutics Inc overvalued?
        According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Ovid Therapeutics Inc pay dividends?
          Ovid Therapeutics Inc does not currently pay dividends.
          What is Ovid Therapeutics Inc’s EPS estimate?
          Ovid Therapeutics Inc’s EPS estimate is -$0.17.
            How many shares outstanding does Ovid Therapeutics Inc have?
            Ovid Therapeutics Inc has 70,491,510 shares outstanding.
              What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
              Ovid Therapeutics Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.172. Following the earnings report the stock price went up 0.5%.
                Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
                Among the largest hedge funds holding Ovid Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Ovid Therapeutics Inc’s shares valued at 3M.


                  Ovid Therapeutics Stock Smart Score

                  The Ovid Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Ovid Therapeutics Inc

                  Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.


                  Top 5 ETFs holding OVID

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold OVID. The ETFs are listed according to market value of OVID within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Cue Biopharma
                  Taysha Gene Therapies
                  Larimar Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis